Current and future gene‐based therapies for Usher syndromes

Inherited retinal dystrophies are a group of genetically and clinically heterogeneous disorders characterized by photoreceptor degeneration. One common example is retinitis pigmentosa (RP), which is characterized by impaired night vision and progressively decreasing peripheral vision. Moreover, RP c...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica (Oxford, England) England), 2019-12, Vol.97 (S263), p.n/a
Main Author: Kalatzis, Vasiliki
Format: Article
Language:English
Subjects:
Deafness
Genomes
Night vision
Peripheral vision
Retina
Retinal degeneration
Retinitis
Retinitis pigmentosa
USH2A protein
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inherited retinal dystrophies are a group of genetically and clinically heterogeneous disorders characterized by photoreceptor degeneration. One common example is retinitis pigmentosa (RP), which is characterized by impaired night vision and progressively decreasing peripheral vision. Moreover, RP can be present as either an isolated visual defect or in association with extra ocular symptoms. The most common syndromic form is Usher syndrome, which is characterized by RP associated with neurosensory deafness of varying severity. The difficulty of this double handicap demands the development of novel therapies. The advantage of the Usher syndrome group is that each disease is monogenic thus lending themselves to gene‐based therapies. The caveat is that the most common forms are due to mutations in large genes, thus rendering gene replacement challenging. This talk will present an overview of current gene‐based therapies for Usher syndrome as a whole and will concentrate on novel genome‐editing advances for the most prevalent causative gene, USH2A.
ISSN:1755-375X
1755-3768
DOI:10.1111/j.1755-3768.2019.8219